Dermapharm Holding SE sees mixed financial outcomes in 2025

In 2025, Dermapharm Holding SE reported a 1.3% decline in consolidated revenue, reaching EUR 1,165.0 million, following the phase-out of low-margin products in its "Parallel import business" segment. Despite the revenue dip, adjusted consolidated EBITDA rose by 2.9% to EUR 324.8 million, with an improved margin of 27.9%. Unadjusted EBITDA also increased by 2.8% to EUR 317.6 million, driving a margin enhancement to 27.3%.

The "Branded pharmaceuticals" segment saw a 5.2% revenue growth, led by robust sales in existing products and the inclusion of F. Trenka's offerings. Conversely, the "Other healthcare products" segment remained stable, with a minor revenue decline attributed to Arkopharma's ongoing business model reorganization. Revenue in the "Parallel import business" segment fell by 18.9%, influenced by portfolio restructuring efforts.